I vaguely remember reading a GS analyst report on it and they considered it worth 50 a share, but were not that hopeful on it being a sucess. It was a report on the R&D pipeline and so they "risk adjusted" all the potential drugs based on chances of sucess multipled by market potential. I think other media reporting on the drug have suggested it could earn $1b a year in revenue at high profit margin, perhaps others can confirm or clarify? I'll take a stab and guess that if it's successful the stock could re-rate 10%.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)